WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 22, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--May 25, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 24, 2018-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 18, 2020-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 25, 2018-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee , Ph.D. has been appointed Executive Vice President and Chief Business Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 21, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Daniel Char , JD, has been appointed Senior Vice President and Chief Legal Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 22, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Helen M. Thackray , MD, FAAP to its Board of Directors.
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 24, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 16, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith has been appointed Senior Vice President and Chief Commercial Officer.